Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus: Nine of 14 analysts rate Monopar Therapeutics a buy, two a strong buy, two a hold, and one a sell. The average 12-month price target is $120.08, above the stock’s $104.33 opening price.
• Shares have pulled back but remain well above their 52-week low: MNPR was down 3.7%, with a 52-week range of $50.07 to $124.82 and a market capitalization of approximately $700 million.
• The company slightly exceeded quarterly earnings expectations, reporting a loss of $0.62 per share versus the $0.64 consensus estimate. Two directors also sold shares under pre-arranged Rule 10b5-1 plans, while Monopar continues developing camsirubicin, an investigational cancer treatment intended to reduce the heart-related toxicity of conventional doxorubicin.

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) have earned an average recommendation of "Moderate Buy" from the fourteen research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, nine have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $120.0833.

A number of analysts have weighed in on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. Morgan Stanley reaffirmed an "overweight" rating and set a $130.00 price objective on shares of Monopar Therapeutics in a research report on Monday, August 17th. Cantor Fitzgerald downgraded Monopar Therapeutics from an "overweight" rating to a "neutral" rating and increased their price objective for the company from $109.00 to $119.00 in a report on Thursday, August 13th. HC Wainwright raised their target price on Monopar Therapeutics from $105.00 to $125.00 and gave the stock a "buy" rating in a research report on Wednesday, July 22nd. Finally, UBS Group set a $125.00 target price on Monopar Therapeutics in a research note on Thursday, July 23rd.

Monopar Therapeutics Stock Down 3.7%

NASDAQ MNPR opened at $104.33 on Wednesday. Monopar Therapeutics has a 52 week low of $50.07 and a 52 week high of $124.82. The firm has a 50 day moving average of $111.92 and a two-hundred day moving average of $79.93. The stock has a market capitalization of $700.05 million, a PE ratio of -48.08 and a beta of 1.49.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, beating analysts' consensus estimates of ($0.64) by $0.02. On average, equities research analysts expect that Monopar Therapeutics will post -2.94 earnings per share for the current fiscal year.

Insider Activity at Monopar Therapeutics

In other news, Director Raymond Anderson sold 3,142 shares of the company's stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $111.77, for a total value of $351,181.34. Following the completion of the transaction, the director owned 23,751 shares in the company, valued at approximately $2,654,649.27. This represents a 11.68% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kim R. Tsuchimoto sold 4,090 shares of the company's stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $111.39, for a total transaction of $455,585.10. Following the completion of the transaction, the director owned 7,396 shares of the company's stock, valued at approximately $823,840.44. The trade was a 35.61% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 9.70% of the company's stock.

Institutional Investors Weigh In On Monopar Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd acquired a new position in Monopar Therapeutics in the fourth quarter valued at $86,000. Your Advocates Ltd. LLP acquired a new stake in shares of Monopar Therapeutics during the first quarter worth about $183,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Monopar Therapeutics in the 1st quarter valued at about $250,000. Sei Investments Co. boosted its position in shares of Monopar Therapeutics by 9.5% in the 1st quarter. Sei Investments Co. now owns 7,582 shares of the company's stock valued at $415,000 after purchasing an additional 656 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of Monopar Therapeutics in the 4th quarter valued at about $654,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer. The company's programs are designed to address significant limitations associated with existing cancer therapies, including treatment resistance and dose-limiting toxicity.

Monopar's lead clinical program is camsirubicin, an investigational next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The drug is designed to retain the anticancer activity of anthracyclines while reducing the risk of cumulative heart damage associated with conventional doxorubicin.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.